- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about AZN
Recent news which mentions AZN
From Benzinga
Repeat COVID-19 Infection Increases Risk Of Acute Outcomes, Long COVID Symptoms, Study Shows
November 11, 2022
From Benzinga
AstraZeneca PLC (AZN) Q3 2022 Earnings Call Transcript
November 10, 2022
Tickers
AZN
From Motley Fool
From Benzinga
From Benzinga
Worried About a Recession? Park Your Money In These 2 High-Yielding Dividend Stocks
November 10, 2022
From Motley Fool
AstraZeneca Ditches US Application Submission For COVID-19 Shot, Q3 Edges Analyst Expectations On Oncology Strength
November 10, 2022
From Benzinga
AstraZeneca lifts guidance after forecast-beating profit and sales
November 10, 2022
Tickers
AZN
From MarketWatch
From Benzinga
FDA Adcomm Backs AstraZeneca's 2-In-1 Asthma Inhaler, Only For Adults Being Less Sure For Adolescents, Kids
November 09, 2022
From Benzinga
Options Traders Expect AstraZeneca Shares To Fall After Earnings Report, As Stock Is Up 5% In 2022
November 09, 2022
Tickers
AZN
From Benzinga
Why Are Apellis Pharmaceuticals Shares Falling Today?
November 04, 2022
From Benzinga
Europe Approves AstraZeneca-Sanofi Partnered Antibody To Prevent RSV Infection In Infants
November 04, 2022
From Benzinga
Why Horizon Therapeutics' Shares Rose 11.32% on Wednesday
November 02, 2022
From Motley Fool
Sorrento Has Potential To Deliver Multiple Best-In-Class Products
November 02, 2022
From Benzinga
Hurry! 7 Pitiful Nasdaq Stocks to Sell Before 2022 Ends.
November 01, 2022
From InvestorPlace
Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know
November 01, 2022
From Benzinga
From MarketWatch
From Benzinga
15 Global Psychedelics Executives To Keep An Eye On In 2022
October 28, 2022
From Benzinga
Why Invitae Stock Was So Healthy This Week
October 28, 2022
From Motley Fool
Ranking 7 Top Tech Stocks to Buy From Biggest to Smallest
October 28, 2022
From InvestorPlace
3 Perfect Stocks Retirees Can Buy Hand Over Fist Right Now
October 28, 2022
From Motley Fool
AstraZeneca's Ultomiris Showed Zero Relapses In Patients With Chronic Disorder Of Brain, Spinal Cord
October 27, 2022
From Benzinga
From Benzinga
From Benzinga
AstraZeneca Touts Positive Data From Two Experimental Drugs In Breast Cancer Settings
October 26, 2022
From Benzinga
AstraZeneca says advanced trial of breast-cancer drug Capivasertib meets primary endpoints
October 26, 2022
Tickers
AZN
From MarketWatch
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.